- Home
- NYC vs UBX Comparison
NYC vs UBX Comparison
Compare NYC & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- UBX
- Stock Information
- Founded
- NYC 2013
- UBX 2009
- Country
- NYC United States
- UBX United States
- Employees
- NYC N/A
- UBX N/A
- Industry
- NYC Real Estate
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- NYC Finance
- UBX Health Care
- Exchange
- NYC Nasdaq
- UBX Nasdaq
- Market Cap
- NYC 23.8M
- UBX 24.6M
- IPO Year
- NYC N/A
- UBX 2018
- Fundamental
- Price
- NYC $8.77
- UBX $1.21
- Analyst Decision
- NYC
- UBX Strong Buy
- Analyst Count
- NYC 0
- UBX 2
- Target Price
- NYC N/A
- UBX $8.00
- AVG Volume (30 Days)
- NYC 3.9K
- UBX 71.9K
- Earning Date
- NYC 11-12-2024
- UBX 11-04-2024
- Dividend Yield
- NYC N/A
- UBX N/A
- EPS Growth
- NYC N/A
- UBX N/A
- EPS
- NYC N/A
- UBX N/A
- Revenue
- NYC $62,061,000.00
- UBX N/A
- Revenue This Year
- NYC N/A
- UBX N/A
- Revenue Next Year
- NYC $3.18
- UBX N/A
- P/E Ratio
- NYC N/A
- UBX N/A
- Revenue Growth
- NYC N/A
- UBX N/A
- 52 Week Low
- NYC $5.46
- UBX $1.11
- 52 Week High
- NYC $10.91
- UBX $2.26
- Technical
- Relative Strength Index (RSI)
- NYC 47.92
- UBX 38.65
- Support Level
- NYC $8.54
- UBX $1.11
- Resistance Level
- NYC $8.96
- UBX $1.37
- Average True Range (ATR)
- NYC 0.31
- UBX 0.09
- MACD
- NYC -0.01
- UBX 0.00
- Stochastic Oscillator
- NYC 45.49
- UBX 35.59
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.